391 Health-related quality of life following [18F]FDG-PET/CT 7 Table 1. Patient baseline demographics, clinical characteristics, and HRQoL timing Diagnostic surgery Active surveillance malignant benign n=29 % n=74 % n=23 % p Female 16 55% 65 88% 21 91% <0.001a Age (years) (mean ± SD) 56.3 ± 14.5 53.5 ± 12.4 54.7 ± 16.0 0.61b General medical history 26 90% 63 85% 19 83% 0.75a Cardiovascular disease (incl. stroke) 11 38% 21 28% 6 26% 0.57a Malignancy 3 10% 7 9% 2 9% 0.98a Haematological disease (incl. malignancy) 3 10% 6 8% 1 4% 0.73a Neurological disease (excl. stroke) 6 21% 15 20% 6 26% 0.83a Otolaryngology disorders 5 17% 14 19% 4 17% 0.97a Lung disease 4 14% 11 15% 3 13% 0.97a Gastro-intestinal disease 8 28% 21 28% 5 22% 0.82a Urological or gynaecological disease 9 31% 27 36% 7 30% 0.80a Endocrine disease (excl. thyroid) 6 21% 9 12% 4 17% 0.52a Musculoskeletal disorder 14 48% 26 35% 7 30% 0.35a Psychiatric disorder 2 7% 4 5% 1 4% 0.92a Thyroid function TSH, mU/L (median, IQR) 1.61 (1.09-2.35) 1.54 (0.92-2.40) 1.42 (0.48-2.20) 0.46c fT4, pmol/L (median, IQR) 14.45 (13.18-16.20) 14.30 (13.10-15.95) 15.05 (13.43-17.18) 0.62c Thyroid US Solitary nodule 22 76% 53 72% 13 57% 0.28a Multinodular disease 7 24% 21 28% 10 43% US nodule size, mm (median, IQR) 37 (27-50) 35 (25-40) 36 (16-47) 0.47c TNM stage T1a 1 3% T1b 5 17% T2 13 45% T3 10 34% N0/x 27 93% N1a 2 7% N1b 0 0% M0 29 100% Highest educational level completed (n=118) Primary school 0 0% 4 6% 2 9% 0.12a Pre-vocational secondary education 7 10% 7 25% 6 27% High school 1 4% 5 7% 2 9% Vocational education 7 25% 12 18% 4 18% Higher professional education 5 18% 30 44% 6 35% University 8 29% 10 15% 2 9% Employment status (n=115) Fulltime job 7 26% 14 21% 3 14% 0.15a Parttime job 9 33% 37 55% 8 38% Unemployed 11 41% 16 24% 10 48% Average work hours (hours/week) (median, IQR) 18 (0-36) 24 (6-32) 8 (0-30) 0.21c Time from baseline HRQoL assessment in months (median, IQR) to [18F]FDG-PET/CT scan (n=115) -0.1 (-0.3-0) -0.2 (-0.7-0) 0 (-0.6-0) 0.28c to diagnostic surgery (n=94) 1.9 (1.3-3.6) 1.8 (1.2-3.5) 0.52d to cTT (n=17) 5.6 (2.7-6.8) RAI (n=16) 6.3 (3.6-8.4) to follow-up US (n=21) 10.6 (9.3-11.4) to 3-month HRQoL assessment (n=105)* 3.1 (3.0-3.4) n=23 3.0 (2.8-3.3) n=62 3.0 (2.9-3.6) n=20 0.30c to 6-month HRQoL assessment (n=103)* 5.9 (5.9-6.0) n=23 6.0 (5.8-6.4) n=60 6.0 (5.8-6.6) n=20 0.81c to 12-month HRQoL assessment (n=104)* 11.9 (11.8-12.1) n=23 11.9 (11.8-12.2) n=60 12.0 (11.8-12.3) n=21 0.95c
RkJQdWJsaXNoZXIy MTk4NDMw